Literature DB >> 23165125

Urological cancer. The benefits of intermittent androgen-deprivation therapy.

Timur Mitin1, Jason A Efstathiou, William U Shipley.   

Abstract

The large randomized study by Crook et al. demonstrated that intermittent administration of androgen deprivation therapy should be considered the standard of care when patients with moderate and well-differentiated localized prostate cancer are treated for rising PSA levels after definitive radiotherapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23165125     DOI： 10.1038/nrclinonc.2012.201

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

2.  Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

Authors:  William U Shipley; Michelle Desilvio; Michael V Pilepich; Mack Roach; Harvey B Wolkov; William T Sause; Philip Rubin; Colleen A Lawton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

3.  The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Authors:  Arto J Salonen; Kimmo Taari; Martti Ala-Opas; Jouko Viitanen; Seppo Lundstedt; Teuvo L J Tammela
Journal:  J Urol       Date:  2012-04-11       Impact factor: 7.450

4.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.

Authors:  K Akakura; N Bruchovsky; S L Goldenberg; P S Rennie; A R Buckley; L D Sullivan
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

Review 6.  Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.

Authors:  Max Peters; Maaike R Moman; Henk G van der Poel; Henk Vergunst; Igle Jan de Jong; Peter L M Vijverberg; Jan J Battermann; Simon Horenblas; Marco van Vulpen
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

7.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096

8.  Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

Authors:  Jean de Leval; Philippe Boca; Enis Yousef; Hubert Nicolas; Michel Jeukenne; Laurence Seidel; Christian Bouffioux; Luc Coppens; Pierre Bonnet; Robert Andrianne; David Wlatregny
Journal:  Clin Prostate Cancer       Date:  2002-12
  8 in total
  2 in total

Review 1.  Asian trends in primary androgen depletion therapy on prostate cancer.

Authors:  Hideyuki Akaza
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

Review 2.  Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.

Authors:  Per-Anders Abrahamsson
Journal:  Asian J Urol       Date:  2017-04-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.